FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 286 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... February 2, 2022 FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... February 23, 2021 ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March February 23, 2021 In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 Load more HOT NEWS New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... ESMO Congress 2023, 20-24 October 2023 Madrid, Spain Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι...
